• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine. A live bivalent influenza vaccine based on a H9N2 virus strain.

Giuseppe

Emeritus
Vaccine. 2009 Nov 2. [Epub ahead of print]

A live bivalent influenza vaccine based on a H9N2 virus strain.

Wu R, Guan Y, Yang Z, Chen J, Wang H, Chen Q, Sui Z, Fang F, Chen Z. - State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, Hubei, China; Graduate University of Chinese Academy of Sciences, Beijing 100049, China.

The purpose of this study was to construct an H9N2 virus-based bivalent live vaccine expressing the protective antigen of a different subtype of influenza virus. Reverse genetics was used to generate an influenza virus containing nine gene segments derived from the A/Chicken/Jiangsu/11/2002 (H9N2) strain, including independent M1 and M2 matrix gene segments. A recombinant virus expressing the H1N1 HA1 hemagglutinin protein was produced on this framework by substituting the extracellular domain of the H9N2 M2 gene with the H1N1 HA1 fragment from A/PR/8/34 (PR8, H1N1). The resulting hybrid virus H9N2-PR8/HA1 was genetically stable and of low pathogenicity. Intra-nasal immunization of BALB/c mice with H9N2-PR8/HA1 virus induced both anti-H9N2 virus and anti-PR8 HA antibodies and conferred protection to mice against lethal challenge (40x LD(50)) with either H1N1 or H9N2 viruses. This study provides a new influenza H9N2 virus model for the expression and/or delivery of foreign antigens.

PMID: 19892041 [PubMed - as supplied by publisher]
-
------


http://www.ncbi.nlm.nih.gov/sites/entrez
 
Last edited by a moderator:
Back
Top Bottom